These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 33839046)
1. Antifibrotics in systemic sclerosis. Martin-Lopez M; Carreira PE Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101671. PubMed ID: 33839046 [TBL] [Abstract][Full Text] [Related]
2. Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease. Yamasaki Y; Kuwana M Expert Rev Clin Immunol; 2020 Jun; 16(6):547-560. PubMed ID: 32506975 [TBL] [Abstract][Full Text] [Related]
3. The role of antifibrotic therapies in the treatment of systemic sclerosis-associated interstitial lung disease. Boleto G; Avouac J; Allanore Y Ther Adv Musculoskelet Dis; 2022; 14():1759720X211066686. PubMed ID: 35111241 [TBL] [Abstract][Full Text] [Related]
4. Should we use nintedanib as early therapy in patients with SSc-ILD? Zanatta E; Moccaldi B; Szucs G; Spagnolo P Autoimmun Rev; 2024 Jan; 23(1):103463. PubMed ID: 37844857 [TBL] [Abstract][Full Text] [Related]
5. [Modern drug therapy for systemic sclerosis associated interstitial lung disease]. Aringer M; Koschel D; Krause A; Schneider U; Gläser S Dtsch Med Wochenschr; 2022 Feb; 147(4):179-186. PubMed ID: 34861699 [TBL] [Abstract][Full Text] [Related]
10. Current advances in the treatment of systemic sclerosis. Bukiri H; Volkmann ER Curr Opin Pharmacol; 2022 Jun; 64():102211. PubMed ID: 35447517 [TBL] [Abstract][Full Text] [Related]
11. Pharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidence. Vonk MC; Smith V; Sfikakis PP; Cutolo M; Del Galdo F; Seibold JR Autoimmun Rev; 2021 Dec; 20(12):102978. PubMed ID: 34718159 [TBL] [Abstract][Full Text] [Related]
12. Interstitial Lung Disease: How Should Therapeutics Be Implemented? Bruni C; Campochiaro C; de Vries-Bouwstra JK Rheum Dis Clin North Am; 2023 May; 49(2):279-293. PubMed ID: 37028835 [TBL] [Abstract][Full Text] [Related]
13. Management of systemic sclerosis: the first five years. Roofeh D; Khanna D Curr Opin Rheumatol; 2020 May; 32(3):228-237. PubMed ID: 32205570 [TBL] [Abstract][Full Text] [Related]
14. Nintedanib downregulates the profibrotic M2 phenotype in cultured monocyte-derived macrophages obtained from systemic sclerosis patients affected by interstitial lung disease. Soldano S; Smith V; Montagna P; Gotelli E; Campitiello R; Pizzorni C; Paolino S; Sulli A; Cere A; Cutolo M Arthritis Res Ther; 2024 Mar; 26(1):74. PubMed ID: 38509595 [TBL] [Abstract][Full Text] [Related]
15. Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD). Jee AS; Corte TJ Drugs; 2019 Sep; 79(14):1511-1528. PubMed ID: 31399860 [TBL] [Abstract][Full Text] [Related]
16. [How do I treat interstitial lung disease in systemic sclerosis?]. Riemekasten G Z Rheumatol; 2021 Feb; 80(1):69-72. PubMed ID: 33340058 [TBL] [Abstract][Full Text] [Related]